November 9, 2021 – Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
VANCOUVER, British Columbia–(BUSINESS WIRE)–Nov. 9, 2021– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, together with its partner BeiGene, the launch of HERIZON‑GEA‑01. This is a randomized, global Phase 3 study evaluating Zymeworks’ investigational HER2‑targeted bispecific antibody, zanidatamab, plus chemotherapy, with or without BeiGene’s anti-PD‑1‑targeted antibody tislelizumab, versus standard of care (trastuzumab plus chemotherapy), for the first-line treatment of metastatic HER2‑postive GEA.
← November 1, 2021 – Taiho Press Release: Taiho Oncology Joins with Advocacy Partners to Underscore the Role of Proper Nutrition for Patients with Stomach Cancer During the Holiday Season and BeyondApril 28, 2022 – Zymeworks Reports Last Patient Enrolled In Pivotal Study Of Zanidatamab In Treatment Of HER2-Expressing Late-Line Biliary Tract Cancer →